Arris Pharmaceutical Articles
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
BM-S & Pharmacopeia In $40 Million Alliance
4 December 1997
Appointment At Arris
27 November 1997
Arris & Sequana Merge In $166 Million Deal
6 November 1997
Arris Plays Down Negative Asthma Trial
2 October 1997
Arris/Merck Join Forces On Protease Inhibitors
25 November 1996
US Biopharma Cos Report 3rd-Qtr Financial Results
11 November 1996
Bayer Opts Into Arris' Tryptase Inhibitor For Asthma
21 October 1996
Arris' Promising Data With Asthma Drug
30 September 1996
Biopharmaceutical Firms Report On 2nd Qtr
12 August 1996
Arris And SKB To Investigate Delta Technology
22 July 1996
Another Angle On Asthma; Arris Pharmaceuticals
27 May 1996
US Corporate Quarterly Results Round-Up
13 May 1996
Tryptase Inhibition For Asthma
6 May 1996
Important Developments For US Biotechnology Cos
19 February 1996
Arris Pharmaceutical / Pharmacia & Upjohn collaboration extended
12 February 1996
Arris/Pharmacia: serine protease inhibitor deal
11 September 1995
Arris Pharmaceuticals Collaboration With Bayer
5 December 1994
ARRIS PHARMA RESEARCH
3 May 1993
Showing 1-19 of 19 articles
- 1
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
